Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 3/2019

01-06-2019 | Guillain-Barré Syndrome | Case Report

Co-existent ulcerative colitis and Guillain–Barré syndrome: a case report and literature review

Authors: Kentaro Tominaga, Atsunori Tsuchiya, Hiroki Sato, Atsushi Kimura, Chiyumi Oda, Kazunori Hosaka, Yuzo Kawata, Naruhiro Kimura, Kazunao Hayashi, Junji Yokoyama, Shuji Terai

Published in: Clinical Journal of Gastroenterology | Issue 3/2019

Login to get access

Abstract

Ulcerative colitis (UC) is a chronic and recurrent inflammatory disease involving the intestine, and Guillain–Barré Syndrome (GBS) is rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system. UC and GBS can be caused by immune system abnormalities and can co-exist. To date, there are 7 reported cases of GBS in patients with UC. However, only one patient developed UC after GBS treatment. We report a rare case of UC that appeared after intravenous immunoglobulin therapy for GBS. This case report and literature review will allow accurate and prompt diagnosis of co-existent GBS and UC.
Literature
1.
2.
Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366:1653–66.CrossRef
3.
Goodfellow JA, Willison HJ. Guillain–Barré syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723–31.CrossRefPubMed
4.
Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain–Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol. 2009;28(suppl 1):53–5.CrossRef
5.
Lossos A, River Y, Eliakim A, et al. Neurologic aspects of inflammatory bowel disease. Neurology. 1995;45:416–21.CrossRefPubMed
6.
Oliveira GR, Teles BC, Brasil EF, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis. 2008;14(3):389–95.CrossRefPubMed
7.
Zimmerman J, Steiner I, Gavish D, et al. Guillain–Barré syndrome: a possible extraintestinal manifestation of ulcerative colitis. J Clin Gastroenterol. 1985;7:301–3.CrossRefPubMed
8.
Saito M, Hozumi I, Kawakami A, et al. A case of post-rubella Guillain–Barré syndrome associated with ulcerative colitis. Rinsho Shinkeigaku. 1994;34(11):1121–4.PubMed
9.
Roca B, Moreno I, Meneu E, et al. Ulcerative colitis and acquired demyelinating neuropathy (Guillain–Barré syndrome). Neth J Med. 1999;54:129–30.CrossRefPubMed
10.
11.
Krystallis CS, Kamberoglou DK, Cheilakos GB, et al. Guillain–Barré syndrome during a relapse of ulcerative colitis: a case report. Inflamm Bowel Dis. 2010;16:555–6.CrossRefPubMed
12.
de la Torre RG, Morís G, Martínez DP, et al. Guillain–Barré syndrome, tuberculosis and inflammatory bowel disease: a multiple association. Int Arch Med. 2010;3:15.CrossRefPubMedPubMedCentral
13.
14.
Braun J, Sieper J. Biological therapies in the spondyloarthritides—the current state. Rheumatology. 2004;43:1072–84.CrossRefPubMed
15.
Silburn S, Mcivor E, Mcentegart A, et al. Guillain–Barre syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis. 2008;67:575–6.CrossRefPubMed
Metadata
Title
Co-existent ulcerative colitis and Guillain–Barré syndrome: a case report and literature review
Authors
Kentaro Tominaga
Atsunori Tsuchiya
Hiroki Sato
Atsushi Kimura
Chiyumi Oda
Kazunori Hosaka
Yuzo Kawata
Naruhiro Kimura
Kazunao Hayashi
Junji Yokoyama
Shuji Terai
Publication date
01-06-2019
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 3/2019
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-00939-1

Other articles of this Issue 3/2019

Clinical Journal of Gastroenterology 3/2019 Go to the issue

Case Report

The successful treatment of hepatocellular carcinoma arising from congenital hepatic fibrosis using radiofrequency ablation under laparoscopy

Case Report

Primary gastrointestinal amyloidosis with gastrointestinal hemorrhage and intestinal pseudo-obstruction: a report of a rare case

Case Report

RETRACTED ​ARTICLE: Intraperitoneal abscess formation spreading to the liver after endoscopic ultrasound-guided fine-needle aspiration for abdominal lymphadenopathy

Case Report

Heterotopic chondroid tissue of the main bile duct mimicking Klatskin tumor: case report and review of the literature

Case Report

Dynamics of hepatitis B virus serum markers in an acute hepatitis B patient in the incubation phase

Case Report

A case of inflammatory fibroid polyp of the stomach with an “erect penis like appearance” successfully removed by endoscopic submucosal dissection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits